News | Contrast Media | September 11, 2015

Ultrasound Pilot Study Shows Positive Results for Treatment of Pancreatic Cancer

Microbubble contrast agent can improve tumor absorption of cancer drugs

ultrasound, microbubbles, delivery, absorption, drugs, pancreatic cancer, ICUS

September 11, 2015 — Tiny gas microbubbles can enhance the delivery and absorption of cancer drugs in patients with advanced pancreatic cancer, according to a new pilot study. The study was described at the International Contrast Ultrasound Society (ICUS) annual conference in Chicago.

One year after their last treatment cycle, two of 10 patients are still alive. 74 percent of pancreatic cancer patients die within the first year of diagnosis. The average life expectancy after diagnosis with metastic pancreatic cancer is just three to six months.

"Our early findings suggested that commercially-available ultrasound microbubbles, combined with a standard chemotherapy drug, might prolong survival in pancreatic cancer patients," according to Odd Helge Gilja, M.D., head of National Centre of Ultrasound in Gastroenterology at Haukeland University Hospital, in Bergen, Norway.

The pilot study included 10 patients with inoperable tumors, and preliminary results in 2014 showed that tumor size was reduced or growth was slowed in the patients, according to Gilja. "The patients treated with ultrasound sonoporation were able to undergo significantly more treatment cycles than those receiving standard chemotherapy. Additional studies are planned to confirm and potentially extend the results," he said.

"The findings are extremely exciting because this study appears to represent the first time ultrasound microbubbles have been used in patients for drug delivery," according to Steven Feinstein, M.D., co-president of ICUS and a professor of medicine at Rush University, Chicago. "If further studies confirm the Bergen findings, ultrasound microbubbles could prove to be an innovative platform option for delivery of drugs and genes to treat other cancers and a wide variety of medical abnormalities throughout the body," he said.

Gilja reported that all 10 patients who participated in the pilot Phase I study received an infusion of a standard chemotherapy drug, gemcitabine, followed by an infusion of a microbubble contrast agent. A customized commercial ultrasound scanner was then used to confirm the presence of the microbubbles in the vicinity of the tumor and to induce "sonoporation," a transient opening and resealing of cell membranes to allow for enhanced delivery and absorption of the cancer drug. Tumor sizes were confirmed by computed tomography (CT) imaging, according to Gilja.

Three ultrasound contrast agents — Definity (Lantheus Medical Imaging), Optison (GE Healthcare) and Lumason (Bracco Diagnostics) — are available in the United States but are approved by the U.S. Food and Drug Administration for cardiac imaging only.

For more information: www.icus-society.org

Related Content

Clarius Releases Clarius Live Ultrasound Telemedicine Solution
Technology | Ultrasound Imaging | May 15, 2019
Clarius Mobile Health released a telemedicine solution called Clarius Live. The simple-to-use feature allows any...
Ultrasonic Device Safe and Effective for Lung Vessel Sealing in Minimally Invasive Lobectomy
News | Interventional Radiology | May 06, 2019
According to a new study, an ultrasonic vessel-sealing device can improve patient outcomes by reducing the incidence of...
Hong Kong Polytechnic University Develops Palm-sized 3-D Scoliosis Ultrasound Imaging System
News | Ultrasound Imaging | May 03, 2019
The Hong Kong Polytechnic University (PolyU) announced the development of a palm-sized 3-D ultrasound imaging system...
Six Predictions on How the Ultrasound Systems Market Will Expand Through 2022
News | Ultrasound Imaging | April 26, 2019
With healthcare costs continuing to rise, affordable and accurate imaging and diagnosis achieved through ultrasound...
ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Ebit and DiA Imaging Analysis Partner on AI-based Cardiac Ultrasound Analysis
News | Cardiovascular Ultrasound | April 16, 2019
DiA Imaging Analysis has partnered with the Italian healthcare IT company Ebit (Esaote Group), to offer DiA’s LVivo...
360 Photos | 360 View Photos | April 12, 2019
This 360 degree view shows staff at the ...
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
DiA Imaging Analysis Introduces LVivo SAX Ultrasound Analysis Tool
Technology | Cardiovascular Ultrasound | April 09, 2019
DiA Imaging Analysis announced the launch of LVivo SAX, a cardiac analysis tool that helps clinicians quickly and...
SuperSonic Imagine Highlights Aixplorer Mach 30 Breast Ultrasound at SBI/ACR Breast Imaging Symposium
News | Ultrasound Women's Health | April 03, 2019
SuperSonic Imagine will introduce the new generation of its Aixplorer Mach 30 breast ultrasound solution at the 2019...